Dergiler / Erciyes Medical Journal / 2015 / Cilt: 37 - Sayı: 3

Prognostic Significance of P53, Bcl-2, and Fas Expression in Patients with Primary Gastrointestinal Diffuse Large B-Cell Lymphoma

Sayfa
102–105
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Taken together, patients with P53 and Bcl-2 expression should be considered to have a high risk from the beginning, and these patients should undergo aggressive treatments

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: P53, Bcl-2, and Fas proteins play significant roles in lymphoid cell apoptosis.
📊
Temel Bulgular & Veri:The aim of the present study was to investigate the effects of P53, Bcl-2, and Fas protein expression on treatment and prognosis in patients with primary gastrointestinal diffuse large B-cell lymphoma.
💡
Sonuç & Katkı:Taken together, patients with P53 and Bcl-2 expression should be considered to have a high risk from the beginning, and these patients should undergo aggressive treatments
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: P53, Bcl-2, and Fas proteins play significant roles in lymphoid cell apoptosis. These proteins affect the prognosis and treatment response of lymphoma and various malignancies. The aim of the present study was to investigate the effects of P53, Bcl-2, and Fas protein expression on treatment and prognosis in patients with primary gastrointestinal diffuse large B-cell lymphoma. Materials and Methods: Thirty-nine patients with primary gastrointestinal diffuse large B-cell lymphoma were included in the study. Immunohistochemical staining was performed to analyze P53, Bcl-2, and Fas protein expression levels in paraffin sections. Results: We examined 39 patients with primary gastrointestinal diffuse large B-cell lymphoma, 21 males and 18 females, with a median age of 54 years. P53 protein expression was detected in 24 patients (61.5%), Bcl-2 protein expression was detected in 26 (67%), and Fas protein expression was detected in 28 (72%). The five-year overall survival rate was significantly lower in patients with P53 and Bcl-2 expression; on the other hand, we did not find a significant difference in the five-year overall survival with respect to Fas protein expression. Conclusion: We found that P53 and Bcl-2 protein expression had a negative effect on prognosis and survival in patients with primary gastrointestinal diffuse large B-cell lymphoma. However, Fas protein expression had no effect on prognosis and survival. Taken together, patients with P53 and Bcl-2 expression should be considered to have a high risk from the beginning, and these patients should undergo aggressive treatments

🔖

Bu Makaleye Atıf Yap

ÇAKMAK, E., SARI, İ., CANÖZ, Ö., ESER, B., ALTUNTAŞ, F., ÇETİN, M., ÜNAL, A. (2015). Prognostic Significance of P53, Bcl-2, and Fas Expression in Patients with Primary Gastrointestinal Diffuse Large B-Cell Lymphoma. Erciyes Medical Journal, Cilt: 37 - Sayı: 3, 102–105. https://ajindex.com/articles/204896

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (3)

  1. Grogan TM, Jaramıllo MA, Miller TP. Natural history, diagnosis, and stagıng of the Non -Hodgkin’s Lymphomas. In: Haskell CM, Berek JS (eds). Cancer Treatment (5th ed). W.B. Saunders Company, Philedelphia, 2001, 1338-75
  2. Vose JM, Chiu BC, Cheson BD. Update on Epidemiology and Therapeutics for Non-Hodgkin‘s Lymphoma. Hematology Am Soc Hematol-Educ Program 2002: 241-62. [CrossRef] 3. Sarpel SC, Paydas S. Non-Hodgkin’s lymphomas in Turkey. Cancer 1988; 62(8): 1653-7. [CrossRef] 4. Arıcan A, Dincol D. Clinicopathologic features and prognostic factors of primary extranodal Non-Hodgkin’s Lymphomas in Turkey. Am J Clin Oncol 1999; 22: 587-92. [CrossRef] 5. Kaufmann SH, Hengartner MO. Programmed cell death: alive and well in the millennium. TRENDS in cell Biology 2001; 11(12): 526- 34. [CrossRef] 6. Voutsadakis IA. Apoptosis and the Pathogenesis of Lymphoma. Acta Oncologica 2000; 39(2):151-6. [CrossRef] 7. Carson DA, Lois A. Cancer progression and p53. The Lancet 1995; 346(8981): 1009-11. [CrossRef] 8. Debatin KM, Stahnke K. Apoptosis in hematological disorders. Seminars in Cancer Biology 2003; 13: 149-58. [CrossRef] 9. Balıga BC, Kumar S. Role of Bcl-2 family of protems m mahgnancy. Hematological Oncology 2002; 20: 63-74. [CrossRef] 10. Sartorius U, Schmitz I, Krammer PH. Molecular Mechanisms of Death- Receptor-Mediated apoptosis. Chembiochem 2001; 2: 20-9. [CrossRef] 11. Saikumar P, Dong Z, Mikhailov V. Apoptosis: definition, Mechanisms and Relevance to Disease. The American Journal of Medicine 1999; 107: 489-506. [CrossRef] 12. Nieder C, Petersen S, Petersen C, Thames HD. The challenge of p53 as prognostic and predictive factor in Hodgkin’s or non-Hodgkin’s lymphoma. Ann Hematol 2001; 80: 2-8. [CrossRef] 13. Navaratnam S,Williams GJ, Rubinger M, Pettigrew NM, Mowat MR, Begleiter A. Expression of p53 predicts treatment failure in aggressive Non-Hodgkin’s lymphomas. Leuk Lymphoma 1998; 29(1-2): 139-44. [CrossRef] 14. Hazar B, Paydas. P53 protein expression in gastrointestinal lymphomas. Oncology 1997; 54(1): 84-7. [CrossRef] 15. Hermine O, Haioun C, Lepage E, dAgay MF, Briere J, Lavignac C, et al. Prognostic significance of the bcl-2 protein expression in agressive Non-Hodgkin’s lymphoma. Blood 1996; 87(1): 265-72
  3. Sanchez E, Chacon I, Plaza MM, Munoz E, Cruz MA, Martinez B et al. Clinical outcome in diffuse large B-cell lymphoma is dependent on the the relationship between different cell-cycle regulator proteins. J Clin Oncol 1998; 16(5): 1931-9